Suppression of T sub(H)17 differentiation and autoimmunity by a synthetic ROR ligand
T-helper cells that produce interleukin-17 (T sub(H)17 cells) are a recently identified CD4 super(+) T-cell subset with characterized pathological roles in autoimmune diseases. The nuclear receptors retinoic-acid-receptor-related orphan receptors alpha and gamma t (ROR alpha and ROR gamma t, respect...
Saved in:
Published in | Nature (London) Vol. 472; no. 7344; pp. 491 - 494 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
08.04.2011
|
Online Access | Get full text |
Cover
Loading…
Summary: | T-helper cells that produce interleukin-17 (T sub(H)17 cells) are a recently identified CD4 super(+) T-cell subset with characterized pathological roles in autoimmune diseases. The nuclear receptors retinoic-acid-receptor-related orphan receptors alpha and gamma t (ROR alpha and ROR gamma t, respectively) have indispensible roles in the development of this cell type. Here we present SR1001, a high-affinity synthetic ligand-the first in a new class of compound-that is specific to both ROR alpha and ROR gamma t and which inhibits T sub(H)17 cell differentiation and function. SR1001 binds specifically to the ligand-binding domains of ROR alpha and ROR gamma t, inducing a conformational change within the ligand-binding domain that encompasses the repositioning of helix 12 and leads to diminished affinity for co-activators and increased affinity for co-repressors, resulting in suppression of the receptors' transcriptional activity. SR1001 inhibited the development of murine T sub(H)17 cells, as demonstrated by inhibition of interleukin-17A gene expression and protein production. Furthermore, SR1001 inhibited the expression of cytokines when added to differentiated murine or human T sub(H)17 cells. Finally, SR1001 effectively suppressed the clinical severity of autoimmune disease in mice. Our data demonstrate the feasibility of targeting the orphan receptors ROR alpha and ROR gamma t to inhibit specifically T sub(H)17 cell differentiation and function, and indicate that this novel class of compound has potential utility in the treatment of autoimmune diseases. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Feature-2 |
ISSN: | 0028-0836 |
DOI: | 10.1038/nature10075 |